A new promising study using stem cells is progressing the fight in eradicating cancer. ASX-listed stem cell biotech Cynata Therapeutics (ASX:CYP) has used its stem cells as part of a pre-clinical study in a mouse model to target various cancers.
The study used genetically engineered stem cells that were derived from mesenchymal stem cells (MSC) manufactured by Cynata’s proprietary Cymerus platform.
MSCs are adult stem cells that can be isolated to produce more than one kind of specialist cell. The cells used in the study were engineered to express diagnostic and therapeutic anti-cancer effects.
The results of the study demonstrated anti-cancer effects of the cells, proving that engineered Cymerus-created stem cells could have highly promising therapeutic benefits in treating cancer.
The studies were conducted under the direction of Professor Khalid Shah, Vice Chair of Research at Brigham and Women’s Hospital in Boston, Massachusetts, and Director of the Center for Stem Cell Therapeutics and Imaging at Harvard Medical School.
Professor Shah said: “Our results validate the use of this cell-based approach. Overall, the study outcomes support the use of engineered Cymerus MSCs for cell therapy to target various malignancies.”
The company also says that this engineering technique could facilitate the creation of novel engineered therapies for areas of high unmet need in other therapeutic areas.
Dr Kilian Kelly, Cynata’s Vice President, Product Development, said: “These highly encouraging results suggest that the Cymerus platform can be exploited to produce targeted anti-cancer therapies, which may have significant advantages over conventional cancer treatments, from both a safety and efficacy perspective.”
Cymerus MSCs were also engineered to express a protein that is known to exert anti-cancer effects. The effects of these engineered Cymerus MSCs on the viability of both human melanoma (skin cancer) and human glioblastoma (brain cancer) cells were evaluated and tested in a well-defined mouse model of glioblastoma.
Cynata continues to pursue the new approach for cancer treatment as part of its product development pipeline.
This content is produced by Star Investing in commercial partnership with Cynata Therapeutics. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Don’t miss a thing, subscribe now